NL-OMON30440撤回3 期
A phase III randomized, double-blind study of sunitinib (SU011248, sutent) versus placebo in patients with progressive advanced/ metastatic well-differentiated pancreatic islet cell tumors - N.A.
适应症
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 发起方
- Pfizer
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Proven diagnosis of well-differentiated pancreatic islet cell tumor.
- •- Locally-advanced or metatstic disease as having shown progression on a scan.
排除标准
- •- Poorly-differentiated pancreatic neuro endocrine tumors
研究者
相似试验
进行中（未招募）
不适用
A PHASE III RANDOMIZED, DOUBLE-BLIND STUDY OF SUNITINIB (SU011248, SUTENT®) VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC WELL-DIFFERENTIATED PANCREATIC ISLET CELL TUMORSEUCTR2006-004022-87-DEPfizer Inc.340
进行中（未招募）
1 期
A PHASE III RANDOMIZED, DOUBLE-BLIND STUDY OF SUNITINIB (SU011248, SUTENT®) VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC WELL-DIFFERENTIATED PANCREATIC ISLET CELL TUMORSProgressive, advanced/metastatic well-differentiated pancreatic islet cell tumoursMedDRA version: 9.1Level: HLTClassification code 10033632Term: Pancreatic neoplasmsEUCTR2006-004022-87-BEPfizer Inc.340
进行中（未招募）
1 期
A PHASE III RANDOMIZED, DOUBLE-BLIND STUDY OF SUNITINIB (SU011248, SUTENT®) VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC WELL-DIFFERENTIATED PANCREATIC ISLET CELL TUMORSProgressive, advanced/metastatic well-differentiated pancreatic islet cell tumoursMedDRA version: 9.1Level: HLTClassification code 10033632Term: Pancreatic neoplasmsEUCTR2006-004022-87-GBPfizer Inc.340
进行中（未招募）
不适用
A PHASE III RANDOMIZED, DOUBLE-BLIND STUDY OF SUNITINIB (SU011248, SUTENT®) VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC WELL-DIFFERENTIATED PANCREATIC ISLET CELL TUMORSProgressive, advanced/metastatic well-differentiated pancreatic islet cell tumoursMedDRA version: 9.1Level: HLTClassification code 10033632Term: Pancreatic neoplasmsEUCTR2006-004022-87-DKPfizer Inc.340
进行中（未招募）
不适用
A PHASE III RANDOMIZED, DOUBLE-BLIND STUDY OF SUNITINIB (SU011248, SUTENT®) VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC WELL-DIFFERENTIATED PANCREATIC ISLET CELL TUMORSProgressive, advanced/metastatic well-differentiated pancreatic islet cell tumoursMedDRA version: 9.1Level: HLTClassification code 10033632Term: Pancreatic neoplasmsEUCTR2006-004022-87-NLPfizer Inc.340